782 related articles for article (PubMed ID: 17785614)
1. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
2. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events.
Seidling V; Hoffmann JH; Enk AH; Hadaschik EN
Acta Derm Venereol; 2013 May; 93(3):346-9. PubMed ID: 23073990
[TBL] [Abstract][Full Text] [Related]
3. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
[TBL] [Abstract][Full Text] [Related]
4. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
Engineer L; Bhol KC; Ahmed AR
J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data.
Gürcan HM; Ahmed AR
Am J Clin Dermatol; 2009; 10(6):383-96. PubMed ID: 19824739
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
[TBL] [Abstract][Full Text] [Related]
7. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study.
Daoud Y; Amin KG; Mohan K; Ahmed AR
Ann Pharmacother; 2005 Dec; 39(12):2003-8. PubMed ID: 16264064
[TBL] [Abstract][Full Text] [Related]
8. Safety of intravenous immunoglobulin (IVIG) therapy.
Katz U; Achiron A; Sherer Y; Shoenfeld Y
Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
[TBL] [Abstract][Full Text] [Related]
9. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
[TBL] [Abstract][Full Text] [Related]
10. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
Sami N; Qureshi A; Ahmed AR
Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
[TBL] [Abstract][Full Text] [Related]
12. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study.
Marazza G; Pham HC; Schärer L; Pedrazzetti PP; Hunziker T; Trüeb RM; Hohl D; Itin P; Lautenschlager S; Naldi L; Borradori L;
Br J Dermatol; 2009 Oct; 161(4):861-8. PubMed ID: 19566661
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulins].
Szép Z; Danilla T; Buchvald D
Cas Lek Cesk; 2005; 144(10):700-3. PubMed ID: 16279438
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
Daoud YJ; Amin KG
Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
[TBL] [Abstract][Full Text] [Related]
16. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
17. Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study.
Letko E; Bhol K; Foster SC; Ahmed RA
Curr Eye Res; 2000 Aug; 21(2):646-54. PubMed ID: 11148601
[TBL] [Abstract][Full Text] [Related]
18. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
Rigas M; Tandan R; Sterling RJ
J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
[TBL] [Abstract][Full Text] [Related]
19. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety.
Gürcan HM; Jeph S; Ahmed AR
Am J Clin Dermatol; 2010; 11(5):315-26. PubMed ID: 20642294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
